INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
03 janv. 2019 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Jan. 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone
18 déc. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Dec. 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology
17 déc. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Dec. 17, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy
04 déc. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and...
Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting
20 nov. 2018 07h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Clinical data from a long-term safety study of pharmaceutical-grade cannabidiol (CBD) oral solution as an investigational treatment for refractory...
INSYS Therapeutics Reports Third Quarter 2018 Results
05 nov. 2018 16h16 HE
|
INSYS Therapeutics, Inc.
Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS...
INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets
05 nov. 2018 16h15 HE
|
INSYS Therapeutics, Inc.
Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development,...
INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular and Intravenous Naloxone for Opioid Overdose
01 nov. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Nov. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), today announced that a pharmacokinetic (PK) study (INS012-18-119) of its proprietary intranasal naloxone spray...
INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5
22 oct. 2018 17h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies
12 oct. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 12, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...